WO2000072836A3 - Methods of promoting or enhancing interleukin-12 production through administration of thalidomide - Google Patents

Methods of promoting or enhancing interleukin-12 production through administration of thalidomide Download PDF

Info

Publication number
WO2000072836A3
WO2000072836A3 PCT/US2000/014784 US0014784W WO0072836A3 WO 2000072836 A3 WO2000072836 A3 WO 2000072836A3 US 0014784 W US0014784 W US 0014784W WO 0072836 A3 WO0072836 A3 WO 0072836A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoting
production
methods
thalidomide
administration
Prior art date
Application number
PCT/US2000/014784
Other languages
French (fr)
Other versions
WO2000072836A8 (en
WO2000072836A2 (en
Inventor
Gilla Kaplan
Stephen J Oliver
Patrick A J Haslett
Original Assignee
Univ Rockefeller
Gilla Kaplan
Stephen J Oliver
Patrick A J Haslett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Gilla Kaplan, Stephen J Oliver, Patrick A J Haslett filed Critical Univ Rockefeller
Priority to AU54483/00A priority Critical patent/AU5448300A/en
Publication of WO2000072836A2 publication Critical patent/WO2000072836A2/en
Publication of WO2000072836A8 publication Critical patent/WO2000072836A8/en
Publication of WO2000072836A3 publication Critical patent/WO2000072836A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Abstract

Methods of promoting or enhancing IL-12 production in patients through administration of thalidomide, or pharmaceutically acceptable salts thereof. The methods are useful in promoting or enhancing IL-12 production in patients suffering from HIV and other infections, tuberculosis, and autoimmune disorders such as sarcoidosis and scleroderma, Crohn's disease and Pyoderma Gangrenosum.
PCT/US2000/014784 1999-05-27 2000-05-26 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide WO2000072836A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54483/00A AU5448300A (en) 1999-05-27 2000-05-26 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32145699A 1999-05-27 1999-05-27
US09/321,456 1999-05-27

Publications (3)

Publication Number Publication Date
WO2000072836A2 WO2000072836A2 (en) 2000-12-07
WO2000072836A8 WO2000072836A8 (en) 2001-09-13
WO2000072836A3 true WO2000072836A3 (en) 2002-01-31

Family

ID=23250688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014784 WO2000072836A2 (en) 1999-05-27 2000-05-26 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide

Country Status (2)

Country Link
AU (1) AU5448300A (en)
WO (1) WO2000072836A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163595A1 (en) 2001-12-21 2003-08-07 Gruenenthal Gmbh 3-position heterocyclic substituted piperidine-2,6-diones
WO2015054374A2 (en) * 2013-10-09 2015-04-16 University Of Miami Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
EP0893122A1 (en) * 1997-07-25 1999-01-27 Ferdinando Ippolito Topical composition comprising thalidomide and their use in cutaneous pathologies
EP0908176A1 (en) * 1997-10-06 1999-04-14 Grünenthal GmbH Intravenous administration form of thalidomide for the therapy of immunologic diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
EP0893122A1 (en) * 1997-07-25 1999-01-27 Ferdinando Ippolito Topical composition comprising thalidomide and their use in cutaneous pathologies
EP0908176A1 (en) * 1997-10-06 1999-04-14 Grünenthal GmbH Intravenous administration form of thalidomide for the therapy of immunologic diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAERT F J ET AL: "Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications.", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 14, no. 1, February 1999 (1999-02-01), pages 47 - 51, XP001015398, ISSN: 0179-1958 *
COSTA I ET AL: "Aseptic adenitis in a patient with pyoderma gangrenosum.", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, vol. 121, no. 8, 1994, pages 550 - 552, XP001015397, ISSN: 0151-9638 *
FARRELL A M ET AL: "Pyoderma gangrenosum of the penis.", BRITISH JOURNAL OF DERMATOLOGY, vol. 138, no. 2, February 1998 (1998-02-01), pages 337 - 340, XP001014538, ISSN: 0007-0963 *
HECKER MELANIE S ET AL: "Recalcitrant pyoderma gangrenosum: Treatment with thalidomide.", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 38, no. 3, March 1998 (1998-03-01), pages 490 - 491, XP001014536, ISSN: 0190-9622 *
KANE S V ET AL: "Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD).", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A745, XP001014511, ISSN: 0016-5085 *
RUSTIN M H A ET AL: "PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCET'S DISEASE TREATMENT WITH THALIDOMIDE", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 23, no. 5 PART 1, 1990, pages 941 - 944, XP001014508, ISSN: 0190-9622 *
VASILIAUSKAS ERIC A ET AL: "An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD).", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A837, XP001014509, ISSN: 0016-5085 *
WEDEL SUSANNE ET AL: "Efficacy of Thalidomide in Crohn's disease.", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A843, XP001014510, ISSN: 0016-5085 *
WETTSTEIN ANTONY R ET AL: "Thalidomide in Crohn's disease.", LANCET (NORTH AMERICAN EDITION), vol. 350, no. 9089, 15 November 1997 (1997-11-15), pages 1445 - 1446, XP000101334, ISSN: 0099-5355 *

Also Published As

Publication number Publication date
WO2000072836A8 (en) 2001-09-13
WO2000072836A2 (en) 2000-12-07
AU5448300A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
BR9916857A (en) 4 heteroaryl diarylamines
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
EP1719770A3 (en) Quinoline derivatives as antibacterials
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2000056362A3 (en) Polycationic carbohydrates as immunostimulants in vaccines
CA2326510A1 (en) Dextran formulations and method for treatment of inflammatory joint disorders
JP2002506648A5 (en)
BR0008228A (en) Compositions of n-benzoyl staurosporine spontaneously dispersible
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
WO1999004772A3 (en) Use of levobupivacaine
PL363431A1 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
IL73957A (en) Inert matrix based on polycaprolactone for the oral administration of a drug and method for the preparation of the galenic form comprising this matrix
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
WO2000072836A8 (en) Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
JP2005525089A5 (en)
WO2000048445A3 (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2000041547A3 (en) Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
GB0021776D0 (en) The treatment of inflammatory disorders
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
AP9901472A0 (en) Crystalline pharmaceutical product.
EP1221945A4 (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 49/2000 UNDER (63) REPLACE THE EXISTING TEXT BY "US, 09/321456 (CON) FILED ON 27.05.99"

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP